Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia [editorial]
Authors:
Open Access
- 15 July 1992
- journal article
- Published by American Society of Hematology in Blood
- Vol. 80 (2) , 302-307
Abstract
PLATELET TRANSFUSIONS are being adminis-P tered at an ever-increasing rate at medical centers in North America, Western Europe, and Japan.' An important cause of this increased demand is the relatively cavalier attitude that many physicians have toward this modality of therapy. However, indiscriminate usage can only account for a fraction of this seemingly unquenchable demand. Undoubtedly, these explosive needs are in large part due to advances in medical technology and greater access to such technologies as cardiac surgery and bone marrow, heart, and liver transplantation. Adaption of the concept of dose intensification as a means of delivering curative therapy to cancer patients, and the human immunodeficiency type 1 (HIV-1) epidemic have also contributed to this platelet supply crisis. Repeated platelet usage, although frequently life-saving, results unfortunately in the inevitable transmission of the many blood-borne infectious diseases as well as alloimmunization.' In addition, the financial burden of this blood product usage is not trivial and likely contributes significantly to the burgeoning of medical costs in our society. Development of alternative strategies to deal with this crisis verges on being a national medical priority. Reversal of these trends will require education of the medical community on the indications for and use of platelet products, and enforcement of these criteria at the local institutional level. All efforts should obviously be directed at expansion of the donor pool, an effort that requires education of members of our society. An alternative approach to meet these needs, which likely will be realized during this decade, is the use of hematopoietic growth factors (HGFs) to promote platelet production and accelerate recovery of platelets after viral, radiation or chemotherapeutic assault upon the marrow. Such a strategy could potentially diminish our need for these blood banking resources. Two reports dealing with interleukin-6 (IL-6), an HGF that potentially will be used for these purposes, appear in this issue of B l o ~d. ~. ~ At present, an HGF with this therapeutic potential is not available to practicing physicians. In addition, several other novel HGFs, including c-kit ligand (KL), IL-1, IL-3, IL-11, and leukemia inhibitory factor (LIF) are also being similarly evaluated. The sudden availability of recombinant HGFs that canKeywords
This publication has 12 references indexed in Scilit:
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid CancerNew England Journal of Medicine, 1991
- Hybrid cytokines as hematopoietic growth factorsStem Cells, 1991
- Human platelet alpha granules contain a nonspecific inhibitor of megakaryocyte colony formation: Its relationship to type β transforming growth factor (TGF‐β)Journal of Cellular Physiology, 1988
- In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor.Journal of Biological Chemistry, 1987
- Purification and properties of a megakaryocyte stimulatory factor present both in the serum-free conditioned medium of human embryonic kidney cells and in thrombocytopenic plasma.Journal of Biological Chemistry, 1987
- Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells.Journal of Clinical Investigation, 1986
- Two‐factor requirement for murine megakaryocyte colony formationJournal of Cellular Physiology, 1982
- Assay of an Activity in the Serum of Patients with Disorders of Thrombopoiesis That Stimulates Formation of Megakaryocytic ColoniesNew England Journal of Medicine, 1981
- Thrombopoiesis‐ and Megakaryocyte Colony‐stimulating Factors in the Urine of Patients with Idiopathic Thrombocytopenic PurpuraBritish Journal of Haematology, 1981
- Thrombopoietin Activity in Mice Following Immune-Induced ThrombocytopeniaActa Haematologica, 1975